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~ CF-asthma and bronchiectasis-asthma: determination with 
AMP bronchoprovocation and sputum properties 
A.T. Aslan 1 , N. Kiper 1 , N. Gurcan 1, O. Keskin 2, O. Kalayci 2, U. Ozcelik 1 , 
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Inhaled and systemic steroid treatment in patients with CF and non-CF bronchiec- 
tasis (BE) remains a debatable subject. The determination f accompanying asthma 
in these patients would be helpful in establishing the response to steroid treat- 
ment. Unfortunately standard efinitions are not particularly helpful in diagnosing 
concomitant asthma. 
This study aims to identify asthma group in CF and non-CF BE patients with 
adenosine monophosphate (AMP) hyper-reactivity. By separating patients in the 
group into those with and without AMP induced hyperreactivity responses, the 
outcomes of induced sputum cell profile were compared. AMP hyper-reactivity 
was tested in 29 bronchial asthmatic patients which chosen as a control group. 
Among the 31 CF and 28 non-CF BE patients tested for bronchial hyperactivity 
with AMR the mean age of patients with CF was 14.1±4.6, and the mean age of 
patients with non-CF BE was 12.8±3.4. Nine patients with CF and 2 patients with 
non-CF BE, AMP hyperreactivity were identified. The mean eosinophil percentage 
was significantly higher in the AMP-positive patient group compared with the AMP 
negative patient group (5.6±10.1 vs 0.5±0.8). AMP hyperreactivity was detected 
in 13 out of 29 bronchial asthmatic patients. 
In CF and non-CF bronchiectatic patients, AMP response could be useful for the 
determination of accompanying asthma. The treatment indication of inhaled or 
systemic steroid medications can be chosen according to the AMP response. 
5. Immunology pulmonology 
~i]  Prevalence of sensitization to moulds in children with CF 
K. McKay 1 , D. Liu-Brennan 2, M. McArthur 1, J. Sercombe 2, E. Tovey 2. 1 The 
Children ~' Hospital at Westmead, 2 Woolcock Institute of Medical Research, Sydney, 
Australia 
Although CF and atopy are genetically unrelated, some studies how more atopy in 
CF subjects that in controls without CE Atopy itself is a major isk factor for asthma 
and may contribute to adverse outcomes in CE We determined the prevalence of 
atopy in children with CF and whether there was an atypical distribution of specific 
allergies. 
Skin prick testing was performed to 6 moulds, and three common allergens: house 
dust mite, cat fur and ryegrass, in 128 children (mean 12.4 yr) with CE The children 
were relatively well nourished with mean height on 36th percentile and weight on 
the 35th percentile and, on average, were mildly affected by CF, with a mean FEV1 
of 79.4% predicted and Shwachman-Kulczycki score of 81. 
Atopy was found in 64.8% of the children. For the total 128 children, atopy 
prevalence was: dust mite 37.5%, cat 14%, ryegrass 21.1% and any mould 53% 
(81.9% of those atopic). In the 68 mould-atopic hildren, 4 were atopic to all 
moulds, 8 to 5 moulds, 8 to 4 moulds, 8 to 3 moulds, 21 to 2 moulds, and 19 to 
only 1 mould. Mould-specific allergies were: Aspergillus fumigatus 74%, Alternaria 
alternata 59%, Cladosporium herbarum 31%, Helminthosporium 43%, Penicillium 
41% and Epicoccum 19%. 
The overall prevalence of atopy in CF children was very high compared to the 
general population, due to increased prevalence of allergy to moulds, which are 
uncommon i  those without CE This may be because CF compromises clearance 
of inhaled moulds, which possibly germinate, further amplifying allergen exposure. 
We are currently studying mould exposure in houses of these children to investigate 
whether those who are atopic, atopic to moulds only, or non-atopic differ clinically. 
This study was supported by a grant from the Australian CF Research Trust. 
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Introduction: ABPA is a hypersensitivity reaction to Aspergillus fumigatus and a 
complication of CE Because ABPA and CF have similar clinical symptoms, the 
diagnosis is difficult and requires pecial annual screening with IgE and RAST for 
Aspergillus in children >6 years old. 
Aims; To record the annual incidence of ABPA for the period 1990~005, to 
correlate ABPA with gender, age, new X-ray findings, pulmonary function, and 
R aeruginosa. 
Material and Methods; 585 CF patients have been screened annually from the 
year of their diagnosis with IgE and RAST for Aspergillus. 
Results: 25 new cases of ABPA were detected, 16 (64%) of which during the last 
five years. 17/25 (68%) were boys. 6/25 (24%) were 0 5 years old, 9/25 (36%) 
6 10 years, 4/25 (16%) 11 15 years and 6/25 (24%) >16 years. The mean 
presentation age of ABPA was 10.5 years. 9/25 (36%) children had new findings 
on chest X-ray examination. The pulmonary function (FEV1), 1 year before the 
diagnosis, was excellent (>100% pred) in 6/18 (33%) patients, very good (71 
100% pred) in 8/18 (44%), good (40 70% pred) in 4/18 (22%). All of the children 
were colonized with Raeruginosa. 
Conclusions: I) 6/25 (24%) of the children that were diagnosed with ABPA were 
under 6 years old, indicating that despite the current belief ABPA is not rare at 
this age group. Therefore, children below 6 years should be routinely screened 
for ABPA. II) There is an important clustering of the disease during the last years. 
III) 9/25 children presented new pulmonary infiltrations or atelectasis, which usually 
lead to permanent pulmonary damage. IV) The pulmonary function was excellent 
or very good before ABPA. 
~2]  Is there a correlation between pseudo-Bartter syndrome and 
pulmonary involvement in Cystic Fibrosis? 
N. Cobanoglu, S. Pekcan, E. Yalcin, D. Dogru, U. Ozcelik, N. Kiper. Hacettepe 
University Pediatric Chest Diseases Unit, Ankara, Turkey 
Metabolic alkalosis with hyponatraemic, hypochloraemic dehydration which is 
defined as pseudo-Bartter syndrome (PB) is a frequent presentation rcomplication 
of cystic fibrosis (CF) in infants and children. Disturbances of airway surface pH 
could contribute to the pathophysiology of CF lung disease. 
Aim: To determine whether there is a correlation between pseudo-Bartter syndrome 
and pulmonary involvement in CF patients. 
Method; We reviewed the previous data of 194 patients with CF followed at 
Hacettepe University Hospital in Ankara, Ttirkiye between January 1987-December 
2005. We compared the data of patients with CF who were treated for PB and 
of patients with CF who never experienced PB, for the number of intravenous 
therapy for pulmonary infections, colonization with Pseudomonas eroginosa nd 
Staphylococcus aureus and the status of pulmonary functions. We used last FEV1 
levels for determining the pulmonary involvement. 
Results; Of 194 patients with CF, 82 patients were treated for PB and 112 patients 
were never experienced PB. There was no significant difference between the 
statistical analysis of the datas of two groups, for intravenous therapy of pulmonary 
infections, colonization with Pseudomonas eroginosa and Staphylococcus aureus, 
and pulmonary functions (p values respectively 0.8; 0.1; 0.1 and 0.3). 
Conclusion: Experiencing PB does not influence the pulmonary involvement in
patients with CE 
